pf-5212365

Cerlapirdine, also known as SAM-531, WAY-262,531 and PF-05212365, is a selective, potent, full antagonist of the 5-hydroxytryptamine 6 (5-HT6) receptor. Cerlapirdine has been in clinical development for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia. As of 2011, it is in phase II clinical trials, and has demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events. It exerts its effects by acting as a selective 5-HT6 receptor antagonist.

Cerlapirdine (PF-05212365) 是一种选择性 5-羟色胺 6 (5-HT6) 受体的完全拮抗剂，用于治疗与阿尔茨海默病和精神分裂症相关的认知障碍。